GANX today
$1.09-$0.02 (-1.80%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $1.34
Key levels
Resistance$1.34
Resistance$1.15
Support$0.94
Latest news & SEC filings
EarningsGain Therapeutics Posts Q3 2026 Results, Issues Business Update
EarningsGain Therapeutics posts smaller Q3 loss than expected
All GANX news →About Gain Therapeutics
Gain Therapeutics is a biotechnology company that develops small molecule drugs for diseases such as central nervous system disorders, lysosomal storage disorders, and metabolic conditions. Its lead candidate, GT-02287, targets Parkinson's disease and is in clinical testing. The company uses its Magellan computational platform to find allosteric binding sites on proteins and design drug candidates. It operates in the United States and Australia.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Gain Therapeutics, Inc. (GANX)
What Is the Price Target for GANX?
SEPT Low Target
$8.00
SEPT Mid Target
$8.00
SEPT High Target
$8.00
Analyst Consensus
$8.00
Is GANX a Buy or Sell Right Now?
Thesis
- •Revenue growing -60.6% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GANX.
Start Free Trial →Is GANX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.17
12
Moat Score
NONE
4/9
Piotroski Score
-3.1
Altman Z-Score
What Is Smart Money Doing with GANX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GANX Growth Story
Revenue YoY
-60.6%
3yr Revenue CAGR
N/A%
EPS Growth YoY
31.46%
FCF Growth YoY
N/A%
Revenue Trend
DECLINING
Dark Pool Trades for GANX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GANX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:08:57 | $1.09 | 1,000 | $$1K | SELL |
| 20:08:29 | $1.09 | 1,000 | $$1K | BUY |
| 20:07:53 | $1.09 | 1,000 | $$1K | BUY |
| 19:55:39 | $1.10 | 3,099 | $$3K | BUY |
| 19:28:54 | $1.11 | 1,000 | $$1K | SELL |
5 dark pool trades shown · $$8K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for GANX
PREVIEWSEPT Investing provides real-time options flow tracking for GANX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $1 | Feb 19 | 99 | $$50 | 2 | SWEEP |
| CALL | $1 | Feb 19 | 99 | $$25 | 1 | SWEEP |
| CALL | $1 | Feb 19 | 99 | $$25 | 1 | SWEEP |
| CALL | $1 | Feb 19 | 99 | $$30 | 1 | SWEEP |
| CALL | $1 | Feb 19 | 99 | $$30 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Gain Therapeutics, Inc. (GANX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GANX — frequently asked questions
What is GANX stock price today?
Gain Therapeutics, Inc. (GANX) is at $1.09, down 1.80% (-$0.02) at the Nov 12, 2026 close.
Why is GANX stock moving today?
Latest GANX news — Nov 10, 2026: Gain Therapeutics Posts Q3 2026 Results, Issues Business Update · Nov 10, 2026: Gain Therapeutics posts smaller Q3 loss than expected
What is the GANX price target?
The average analyst price target for GANX is $8.00, ranging from $8 to $8, based on 1 analysts.
What do analysts rate GANX?
Analyst ratings for GANX: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did GANX beat earnings?
GANX last reported on Aug 11, 2026: EPS -$0.11 vs -$0.14 expected — a beat of 20.3%.
Does GANX pay a dividend?
GANX does not currently pay a dividend.
How much debt does GANX have?
Gain Therapeutics, Inc. reported $0M of debt and $13M of cash (Jun 30, 2026).
What are GANX support and resistance levels?
Support: $0.94. Resistance: $1.15, $1.34, $1.45.
What are insiders doing with GANX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on GANX?
Nov 10, 2026: Gain Therapeutics Posts Q3 2026 Results, Issues Business Update · Nov 10, 2026: Gain Therapeutics posts smaller Q3 loss than expected